{"id":5919,"date":"2021-06-08T05:40:47","date_gmt":"2021-06-08T05:40:47","guid":{"rendered":"https:\/\/swaritadvisors.com\/blog\/?p=5919"},"modified":"2021-06-08T05:44:25","modified_gmt":"2021-06-08T05:44:25","slug":"landmark-judgement-on-patent-in-india","status":"publish","type":"post","link":"https:\/\/swaritadvisors.com\/blog\/landmark-judgement-on-patent-in-india\/","title":{"rendered":"An Overview of Landmark Judgement on Patent in India"},"content":{"rendered":"\n<p class=\"has-drop-cap\">Patent\nProtection is certainly the leading priority for any organisation because it\ncan keep them ahead of rivals and acquires stable income for years to come.\nHowever, some Patents stagger upon unexpected litigations that cost significant\ntime and money for the company. In this blog, we have curated a list of\nlandmark judgement on the Patent that only created the buzz in the authorised\ndomain but also left a lasting impact on the constitutional framework of the\nnation.<\/p>\n\n\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-light-blue ez-toc-container-direction\">\n<p class=\"ez-toc-title\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a2b9c1f59ac8\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a2b9c1f59ac8\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/swaritadvisors.com\/blog\/landmark-judgement-on-patent-in-india\/#Cipla_Ltd_Vs_F_Hoffmann-La_Roche_Ltd_%E2%80%93_Landmark_Judgement_in_India\" title=\"Cipla\nLtd. Vs F. Hoffmann-La Roche Ltd. \u2013 Landmark Judgement in India\">Cipla\nLtd. Vs F. Hoffmann-La Roche Ltd. \u2013 Landmark Judgement in India<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/swaritadvisors.com\/blog\/landmark-judgement-on-patent-in-india\/#Novartis_AG_vs_Union_of_India\" title=\"Novartis\nAG vs Union of India\">Novartis\nAG vs Union of India<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/swaritadvisors.com\/blog\/landmark-judgement-on-patent-in-india\/#TVS_Motor_Company_Ltd_Vs_Bajaj_Auto_Ltd_%E2%80%93_Landmark_Judgement_on_Patent\" title=\"TVS\nMotor Company Ltd. Vs Bajaj Auto Ltd. \u2013 Landmark Judgement on Patent\">TVS\nMotor Company Ltd. Vs Bajaj Auto Ltd. \u2013 Landmark Judgement on Patent<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/swaritadvisors.com\/blog\/landmark-judgement-on-patent-in-india\/#Cadila_Healthcare_Ltd_Vs_Glochem_Industries\" title=\"Cadila Healthcare Ltd. Vs Glochem Industries\">Cadila Healthcare Ltd. Vs Glochem Industries<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/swaritadvisors.com\/blog\/landmark-judgement-on-patent-in-india\/#Anrvs_Union_of_India_Bayer_Corporation_Ors\" title=\"Anrvs\nUnion of India &amp; Bayer Corporation &amp; Ors\">Anrvs\nUnion of India &amp; Bayer Corporation &amp; Ors<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/swaritadvisors.com\/blog\/landmark-judgement-on-patent-in-india\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Cipla_Ltd_Vs_F_Hoffmann-La_Roche_Ltd_%E2%80%93_Landmark_Judgement_in_India\"><\/span>Cipla\nLtd. Vs F. Hoffmann-La Roche Ltd. \u2013 Landmark Judgement in India<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Two\npharmaceutical companies, viz OSI Pharmaceuticals and Hoffmann-La Roche Ltd., have\nfiled the petition for an enduring injunction of the drug due to Patent Infringement,\ninterpretation of damages, accounts, &amp; delivery against Cipla Ltd. Mumbai. <\/p>\n\n\n\n<ul><li>Indian drug manufacturer Cipla\nwon the landmark judgement against Roche in Delhi High court over the broad\nversion of cancer treatment drug Eriotinib. The case was unique and distinctive\nas it is the first Patent litigation in the nation, which comprises pricing\nissues &amp; public interest that prevent evergreening of the Patent.<\/li><li>The next petition of Roche to\nthe division bench also rejected in light of the trial findings of the judge.\nAlso, the Court obtruded a cost on Roche for suppression of information\nregarding the eventually filed the application in India\n(IN\/PCT\/2002\/00507\/DEL).<\/li><li>The proposed Patent application\nwas on Polymorph Form B of Eroltinib Hydrochloride, which faces dissatisfaction\nin 2008 following the petition filed Cipla on Section 3d. Cipla claimed that\nTarceva agrees to Polymorphic Form B is more steady and appropriate for oral\ndosage than the mixture available in 774 Patent comprise a mixture of Form A\n&amp; B,<\/li><li>In the year 2008, Roche sued\nCipla before <strong><em>Delhi High Court, <\/em><\/strong>appealing that the common product Erlocip violates\nthe former Indian 774 Patent claiming \u201cErlotinib Hydrochloride\u201d. But, the trial\njudge declines the petition to bequeath injunction preventing Cipla from\nselling an inexpensive version of Tarceva on a version of public interest &amp;\nincomplete Patent proceedings against 774 Patent. Cipla\u2019s inexpensive version\nof the drug prices around 1\/3 of Roche\u2019s patented medicine.<\/li><li>Before the Supreme Court, the\nnext petition of Roche against an order issued by the section bench got\ndisapproved due to an in-progress trial at the Delhi High Court.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Novartis_AG_vs_Union_of_India\"><\/span>Novartis\nAG vs Union of India<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Yet another landmark judgement of the <a href=\"https:\/\/swaritadvisors.com\/patent-registration\" class=\"text-primary\"><strong>Patent Registration<\/strong><\/a> in India created a lot of tinkle in the drug manufacturing domain. This time Swiss Drug manufacturer Novartis faces refusal from the Patent control in the light of \u201cunconstitutional\u201d Patent law practices. The Swiss giant search a Patent for its cancer drug, Glivec; however, the Government cancelled their appeal on the ground of the given facts:<\/p>\n\n\n\n<ul><li>The drug was neither\ndistinctive nor innovative as per the Patent Law;<\/li><li>The Patent was already approved\nfor imatinib, which is an active ingredient of Glivec;<\/li><li>The drug apparently adhered to\nSection 3 (d), which challenges the idea of incremental innovations.<\/li><\/ul>\n\n\n\n<p>As\na result, the Swiss Manufacturer decided to sue the constitutionality of\nSection 3 (d) in the High Court, which was discarded in due consideration of\nthe grounds as mentioned above.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"TVS_Motor_Company_Ltd_Vs_Bajaj_Auto_Ltd_%E2%80%93_Landmark_Judgement_on_Patent\"><\/span>TVS\nMotor Company Ltd. Vs Bajaj Auto Ltd. \u2013 Landmark Judgement on Patent<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>In\nthe case of TVS Motors Company Ltd. Vs, Bajaj Auto Ltd. Tells about the\ndisagreement concerning the illegal application of the Patent of the <strong><em>DTSI\n(Digital Twin Spark Ignition)<\/em><\/strong>. The case is essential on the grounds of\nthe parties\u2019 financial stakes and application of the pith &amp; marrow policy.\nThis case is distinct as it takes Doctrine of Equivalent into account. Above\nall, the principles available in concluding the decision are also essential.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Cadila_Healthcare_Ltd_Vs_Glochem_Industries\"><\/span>Cadila Healthcare Ltd. Vs Glochem Industries<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>In\nthe current landmark judgement, the Bombay High Court took the validity of\npre-grant Patent opposition into the description and announced that a new form\nof an existing substance couldn&#8217;t fall under the regime of Patent unless its\nclaim exceeds prior art to make sure the dissimilar or improving effect.<\/p>\n\n\n\n<ul><li>Glochem industries filed a\npetition prior to the Court after its pre-grant opposition to the Patent\napplication of Cadila was disapproved by the Patent control. The main concerns\nof Glochem were that the Patent claim did not stick to originality and lacked boosting\ntherapeutic effect, as per Section 25 (1) and Section 3(d) of the Indian\nPatents Act.<\/li><li>As per the Glochem, Cadillac\nhad filed to furnish considerable evidence before the Court that the new form\nof substance enhances the efficacy therapeutic. The entity also claimed that\nthe disapproval of the controller\u2019s opposition of the Patent resulted from\nmisapplication &amp; misconstruction of the provisions under Section 3 (d) of\nthe Act.<\/li><\/ul>\n\n\n\n<p>This\nclash revolves around the substance known as clopidogrelbesylate, a salt\nimitative from clopidogrel, which is already patented in the United States. <\/p>\n\n\n\n<p>After\nlong-lasting deliberations, Bombay High Court opined that the previous actions\nof Golcem to control the opposition could act as landmark litigation ground.\nMoreover, the Court cited that the alleged misrepresentation by the Patent\ncontroller could harden the case; therefore, the Court decided to hold the\norder and directed the power to reconsider the matter.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Anrvs_Union_of_India_Bayer_Corporation_Ors\"><\/span>Anrvs\nUnion of India &amp; Bayer Corporation &amp; Ors<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Another\nlandmark judgement that has sounded strongly in the legal domain for years.\nInstead of petition filing for infringement, Bayer Corporation filed a writ\nappeal in the Delhi High Court requesting an injunction on the marketing\nconsent application of Cipla in light of the infringement caused by their\nedition of the drug viz SORANIB.<\/p>\n\n\n\n<p>This\nappeal was one of its types because it links drug consent to a Patent violation\nin India.<\/p>\n\n\n\n<p>In\nreply, the Delhi High Court declined to stamp their approval on such demand and\neventually imposed a cost of Rs. 6,75,000 on the applicant to prevent the\nupcoming occurrence of such actions.<\/p>\n\n\n\n<ul><li>The Delhi High Court, in its judgement, simplified that the Drug-Patent Linkage mechanism is not a practical thing as both the Act removes on particular objectives and rights to check the Patent standard is with the Patent&#8217;s controller regime. Moreover, such linkage may have a radical impact on the country&#8217;s public health policy.<\/li><li>Bayer contends that Section 2 of the <strong>Drugs and Cosmetic Act<\/strong><sup><a href=\"https:\/\/cdsco.gov.in\/opencms\/opencms\/en\/Acts-Rules\/\" class=\"text-primary\"><strong>[1]<\/strong><\/a><\/sup>, in connection with Section 48 of the Indian Patent Act, 1970, establishes a Patent linkage mechanism that prevents anyone from taking marketing consent for a drug over a patented drug. The entity also claimed that the CIPLA&#8217;s &#8220;SORANIB&#8221; is a &#8220;Spurious Drug&#8221; as described under the Drugs Act.<\/li><li>The Court further added that market consent of drug has nothing to take with the Patent violation. Therefore, Patent Infringement cannot come to effect unless it is established in a court law. Such arbitration is beyond the range of jurisdiction of Drug Authorities. This is indeed the landmark judgement when it comes to lawful and judicial complexity.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span>Conclusion<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Patent protection in India is somewhat challenging, considering the influence available within our legal structure. The landmark judgements, as mentioned above, have made it evident that transparency on the applicable law is essential for the applicant before filing a petition against the defaulter for Patent protection.<\/p>\n\n\n\n<p class=\"text-left\"><b>Read our article<\/b>:<mark style=\"background: #fffd03 !important;\"><a href=\"https:\/\/swaritadvisors.com\/blog\/benefits-of-provisional-patent\/\">Benefits of Provisional Patent \u2013 An Overview\n<\/a><\/mark><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Patent Protection is certainly the leading priority for any organisation because it can keep them ahead of rivals and acquires stable income for years to come. However, some Patents stagger upon unexpected litigations that cost significant time and money for the company. In this blog, we have curated a list of landmark judgement on the [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5921,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[55],"tags":[687],"acf":[],"_links":{"self":[{"href":"https:\/\/swaritadvisors.com\/blog\/wp-json\/wp\/v2\/posts\/5919"}],"collection":[{"href":"https:\/\/swaritadvisors.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/swaritadvisors.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/swaritadvisors.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/swaritadvisors.com\/blog\/wp-json\/wp\/v2\/comments?post=5919"}],"version-history":[{"count":13,"href":"https:\/\/swaritadvisors.com\/blog\/wp-json\/wp\/v2\/posts\/5919\/revisions"}],"predecessor-version":[{"id":5934,"href":"https:\/\/swaritadvisors.com\/blog\/wp-json\/wp\/v2\/posts\/5919\/revisions\/5934"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/swaritadvisors.com\/blog\/wp-json\/wp\/v2\/media\/5921"}],"wp:attachment":[{"href":"https:\/\/swaritadvisors.com\/blog\/wp-json\/wp\/v2\/media?parent=5919"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/swaritadvisors.com\/blog\/wp-json\/wp\/v2\/categories?post=5919"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/swaritadvisors.com\/blog\/wp-json\/wp\/v2\/tags?post=5919"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}